Eupraxia Pharmaceuticals Statistics
Total Valuation
EPRX has a market cap or net worth of $434.07 million. The enterprise value is $323.98 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EPRX has 61.81 million shares outstanding. The number of shares has increased by 26.83% in one year.
| Current Share Class | 61.50M |
| Shares Outstanding | 61.81M |
| Shares Change (YoY) | +26.83% |
| Shares Change (QoQ) | +10.56% |
| Owned by Insiders (%) | 18.17% |
| Owned by Institutions (%) | 37.66% |
| Float | 46.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.19 |
| P/TBV Ratio | 4.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.30, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.30 |
| Quick Ratio | 18.95 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.52% and return on invested capital (ROIC) is -35.75%.
| Return on Equity (ROE) | -54.52% |
| Return on Assets (ROA) | -33.84% |
| Return on Invested Capital (ROIC) | -35.75% |
| Return on Capital Employed (ROCE) | -34.25% |
| Weighted Average Cost of Capital (WACC) | 12.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$959,139 |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, EPRX has paid $30,202 in taxes.
| Income Tax | 30,202 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +77.95% in the last 52 weeks. The beta is 1.42, so EPRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | +77.95% |
| 50-Day Moving Average | 7.19 |
| 200-Day Moving Average | 6.78 |
| Relative Strength Index (RSI) | 46.46 |
| Average Volume (20 Days) | 197,121 |
Short Selling Information
The latest short interest is 3.08 million, so 4.98% of the outstanding shares have been sold short.
| Short Interest | 3.08M |
| Short Previous Month | 2.57M |
| Short % of Shares Out | 4.98% |
| Short % of Float | 6.62% |
| Short Ratio (days to cover) | 18.92 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.27M |
| Pretax Income | -44.46M |
| Net Income | -47.00M |
| EBITDA | -47.06M |
| EBIT | -47.27M |
| Earnings Per Share (EPS) | -$1.04 |
Full Income StatementBalance Sheet
The company has $138.88 million in cash and $2.01 million in debt, with a net cash position of $136.87 million or $2.21 per share.
| Cash & Cash Equivalents | 138.88M |
| Total Debt | 2.01M |
| Net Cash | 136.87M |
| Net Cash Per Share | $2.21 |
| Equity (Book Value) | 136.19M |
| Book Value Per Share | 1.75 |
| Working Capital | 134.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.70 million and capital expenditures -$746,856, giving a free cash flow of -$33.44 million.
| Operating Cash Flow | -32.70M |
| Capital Expenditures | -746,856 |
| Depreciation & Amortization | 208,063 |
| Net Borrowing | n/a |
| Free Cash Flow | -33.44M |
| FCF Per Share | -$0.54 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.83% |
| Shareholder Yield | -26.83% |
| Earnings Yield | -10.83% |
| FCF Yield | -7.70% |
Analyst Forecast
The average price target for EPRX is $16.28, which is 134.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.28 |
| Price Target Difference | 134.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
